Introduction: Disulfiram was the first medication approved to treat alcohol dependence and has been found to be safe and efficacious. This cross sectional, observational, qualitative study was conducted with the aim to assess the pattern of dispensation of disulfiram among patients with alcohol use disorder (AUD).

Material And Methods: Data was collected using a customized questionnaire consisting of 32 questions regarding socio-demographic characteristics, psychiatric history, pattern of dispensation of disulfiram/disulfiram-like product (DLP) and related knowledge. Descriptive statistics and frequency distribution tables were used for analysing the data using Microsoft Excel 2013.

Results: Thirty seven percent (n=100) of the total patients with ADS (n=268) screened had a history of administration of disulfiram/DLP. Tablets were the commonest (60%) formulation of disulfiram/DLP advised by the dispenser, only 4% of whom were psychiatrists. Surreptitious administration was preferred by family members (76%). Majority of the patients (44%) received the medication only once or twice.

Limitations: The actual product - disulfiram and/or DLP - could not be chemically tested to confirm the identity. Considering the socio-economic and cultural background where the study was conducted, it would be difficult to generalize the findings.

Discussion: Disulfiram/DLP was prescribed by physicians and faith healers alike. They seem to promote surreptitious administration of disulfiram with full agreement of relatives, thereby potentially exposing the patient to life threatening complications. Hence it is recommended that disulfiram prescription should involve stricter guidelines and DLP like kudzu in traditional/herbal products should also be brought under the same purview as disulfiram.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajp.2017.05.002DOI Listing

Publication Analysis

Top Keywords

administration disulfiram
8
disulfiram patients
8
patients alcohol
8
alcohol disorder
8
study conducted
8
pattern dispensation
8
surreptitious administration
8
disulfiram
7
pattern prescription
4
prescription dispensation
4

Similar Publications

During the proliferative phase of liver regeneration, insufficient regulation of hepatocyte hydrogen peroxide (HO) overproduction can result in oxidative stress and hepatocyte death. This study aims to investigate the influence of Aquaporin 5 (Aqp5) on liver regeneration by evaluating its role in reactive oxygen species (ROS) generation and NLRP3-GSDMD-mediated pyroptosis. A 70 % partial hepatectomy (PHx) model was established in Aqp5 mice to evaluate the pathological changes in the liver.

View Article and Find Full Text PDF

Perturbations in the gut microbiome of C57BL/6 mice by the sobriety aid Antabuse® (disulfiram).

J Appl Microbiol

January 2025

Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25755, United States.

Aims: Disulfiram (Antabuse®) is an oral alcohol sobriety medication that exhibits antimicrobial activity against Gram-positive facultative anaerobes. The aims of this study were to measure the antimicrobial activity against anaerobic bacteria of the gut human microbiome and establish the extent that disulfiram alters the microbial composition of the ileum, cecum, and feces using C57BL/6 mice.

Methods And Results: Antimicrobial susceptibility testing by the microdilution method revealed that disulfiram inhibits the in vitro growth of gut anaerobic species of Bacteroides, Clostridium, Peptostreptococcus, and Porphyromonas.

View Article and Find Full Text PDF

Disulfiram in liver diseases: a double-edged sword.

Naunyn Schmiedebergs Arch Pharmacol

December 2024

Department of Infectious Disease, The First Hospital of Lanzhou University, No.1 Donggang West Road, Chengguan District, Lanzhou City, 730000, Gansu Province, China.

Disulfiram, a synthetic drug, has historically played a significant role in the treatment of alcoholic liver disease as the first medication approved by the U.S. Food and Drug Administration for alcohol use disorders.

View Article and Find Full Text PDF

Introduction: Disulfiram (DSF) reduces insulin resistance and weight gain in obese mice. However, the effect on adipose tissue is unexplored due to their high instability under physiological conditions, limiting clinical applications. Thus, it is meaningful to develop a DSF carrier for sustained release to adipose tissue.

View Article and Find Full Text PDF

Disulfiram-containing polymeric nanocapsules with anticancer activity for cancer treatment.

Int J Pharm

January 2025

Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA; Supervisor of Shared Research Facilities, School of Pharmacy and Department of Pharmaceutical Sciences, Northeastern University, USA; Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA. Electronic address:

Article Synopsis
  • Disulfiram, a medication previously used for alcohol addiction, is being studied as a cancer treatment due to its ability to inhibit cancer cell growth and enhance the effectiveness of chemotherapy and radiation.
  • The drug induces apoptosis (cell death) in cancer cells and can be effective against various types of cancer, including breast and prostate cancer.
  • Researchers are focusing on new delivery systems, like polycaprolactone-based nanocapsules, which improve the drug's stability and cytotoxicity, suggesting a promising avenue for more effective and safer cancer treatments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!